Dr Reddy’s Sees Revenue Growth Of 25 Percent This Financial Year, Improved Profitability

NEW DELHI - India's second biggest generic drug maker said it expects revenue growth of 25 percent in the financial year started April and gross margins of 50 percent led by improved cost control at its German betapharm unit and growing revenues from custom manufacturing and active pharmaceutical ingredient sales after earnings below expectations for the fourth quarter ended March